On track to file New Drug Applications (NDAs) for NRX-100 (IV Ketamine) in treating suicidal ideation in depression, including bipolar depression and NRX-101 (Oral D-Cycloserine/Lurasidone) for Accelerated Approval in bipolar depression with suicidality or akathisia by year end 2024 with 2025 PDUFA date forecast. HOPE Therapeutics acquiring Interventional Psychiatry Clinics; key to developing a best-in-class network of care to prevent suicide, continues to expect first revenue by year-end 2024. 74% reduction in net operating losses compared to 3 rd quarter 2023 with profitability forecast in 2025 from HOPE Therapeutics and from sales of medication.
Management to host a conference call November 18, 2024 at 4:30 PM ET WILMINGTON, Del. , Nov. 14, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc.
(Nasdaq: NRXP ) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced its financial results for the quarter and year to date ended September 30, 2024 and provided a business update. Key Clinical and Business Activities.
